Isracann Biosciences Inc. (CSE:IPOT) (XFRA:A2PT0E) (OTC:ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is accelerating efforts to service an anticipated increase in demand for both domestic and European markets.

As the current COVID-19 health crisis extends into the second quarter of the year, global supply chains for cannabis are facing new challenges to meet growing demands. Licensed North American and European Cannabis operations require significant and ongoing inputs of fertilizers and nutrients along with extensive skilled labour to ensure their timely ability to plant, grow, harvest, test and receive approval to ship at scale in order to service their domestic and international obligations. As noted in the European Cannabis Report (5th Edition, Feb. 2020) actions to increase domestic European supply are fragmented with Germany in the midst of regulatory framework development, Italy contracting with a Canadian supplier to meet demand and Denmark importing virtually all its supply needs. This environment indicates the overall EU supply is lagging. Combined with the current unprecedented health circumstances, production stressors may result in potential delivery shortfalls, testing existing suppliers’ ability to meet the needs of clinical trials and medical consumers throughout the EU.


Isracann aims to respond to this anticipated undersupply by leveraging Israel’s advanced agronomics, excellent domestic input supply, over 300 days of sunshine annually and access to major Mediterranean shipping routes to create an achievable and rapid path to success. The previously announced distribution partnership on the island of Malta offers obvious financial incentives plus sophisticated and highly regarded EU trading relations, but the Company remains open to a number of intriguing options ensuring rapid transhipment of future harvested goods to the many high value continental markets.

“Regarding our European plans, our Hefer valley farm is making great strides this week,” states VP of Operations Matt Chatterton. “We engaged a specialist Israeli consultant to advance the certification of the farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness and should be completed next week.”

Today, the Company received notification that the local authorities have completed the mandatory security inspection of the facility. No early reports of any deficiencies were identified, and the certification consultant is preparing the final report to the Ministry of Health for recommendation of final approvals. Subsequent plans to advance to planting are imminent and anticipated to commence next week.

Company CEO Darryl Jones notes, “All reports from Israel are highly favourable and we appear to be days away from having seeds in the ground. This news combined with a growing sense of urgency across the domestic and European marketplace is genuinely exciting.”

In related news, the Company wishes to announce that it has granted 2,800,000 stock options at an exercise price of CAD$0.19 to directors and officers of the Company to purchase an aggregate 2,800,000 common shares in the capital of the Company. The stock options are exercisable for a term of three years and vest immediately. The Company has also granted 200,000 stock options at an exercise price of $0.19 to investor relations consultants which vest 25% every 3 months for one year. All stock options are granted in accordance with the terms of the Company’s stock option plan and the policies of the CSE.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. There can be no assurance that such statements, including the impacts of the COVID-19 pandemic and supply and demand trends in the cannabis industry, will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Contact
Investor Relations
Toll Free: +1 855.205.0226
Email: inquiries@isracann.com
Web: www.isracann.com

Click here to connect with Isracann Biosciences Inc. (CSE:IPOT) for an Investor Presentation.

Source

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less